Research programme: enhanced tumour infiltrating lymphocytes - AgonOx/SQZ Biotech
Alternative Names: mRNA engineered tumour infiltrating lymphocytes - SQZ Biotech; SQZ® TILs; TIL - SQZ BiotechLatest Information Update: 14 Sep 2022
At a glance
- Originator AgonOx; SQZ Biotech
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Interleukin 12 replacements; Interleukin 2 replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Malignant melanoma
Most Recent Events
- 13 Sep 2022 Preclinical pharmacodynamic data presented at the European Society for Medical Oncology (ESMO-2022)
- 30 Nov 2021 Enhanced tumour infiltrating lymphocytes - SQZ Biotech is available for licensing as of 30 Nov 2021. https://sqzbiotech.com/work-at-sqz/#contact-us
- 10 Nov 2021 Preclinical trials in Cancer in USA (Parenteral) as of November 2021